Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Medical record

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    468 result(s) found for: Medical record. Displaying page 1 of 24.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-002672-95 Sponsor Protocol Number: UMCNONCO200801 Start Date*: 2008-07-29
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: Studie naar de optimale therapieduur van orale angiogenese remmers
    Medical condition: Patients with a metastatic malignancy, treated with a registered oral angiogenetic inhibitor (tyrosine kinase inhibitor), who have progressive disease according to RECIST on CT-evaluation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003761-99 Sponsor Protocol Number: VX16-809-121 Start Date*: 2018-06-27
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: An Exploratory Phase 2, 2-part, Randomized, Double blind, Placebo controlled Study With a Long term, Open label Period to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjec...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002369-23 Sponsor Protocol Number: 1289-0049 Start Date*: 2019-05-27
    Sponsor Name:Boehringer Ingelheim
    Full Title: A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive the...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10064337 Schizophrenia relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005590-20 Sponsor Protocol Number: Td518 Start Date*: 2016-01-13
    Sponsor Name:SANOFI PASTEUR
    Full Title: Safety Among Adolescents and Adults of Revaccination with Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 4 to 5 Years After a Previous Dose
    Medical condition: Active immunization against tetanus, diphtheria and pertussis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10054129 Diphtheria immunisation PT
    18.1 10042613 - Surgical and medical procedures 10069577 Pertussis immunisation PT
    18.1 10042613 - Surgical and medical procedures 10054131 Tetanus immunisation PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000053-62 Sponsor Protocol Number: sph/itu/0001 Start Date*: 2007-06-18
    Sponsor Name:Ashford & St. Peter's Hospitals NHS Trust
    Full Title: The effects of helium-oxygen gas mixture (Heliox) on airway pressures in mechanically ventilated adult patients with acute lung injury
    Medical condition: Acute lung injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038696 Respiratory failure (excl neonatal) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003292-30 Sponsor Protocol Number: GLPG1837-CL-202 Start Date*: 2016-01-18
    Sponsor Name:Galapagos NV
    Full Title: A phase IIa, open-label study of two doses of GLPG1837 in subjects with cystic fibrosis and the S1251N mutation.
    Medical condition: Cystic fibrosis with the S1251N mutation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005496-87 Sponsor Protocol Number: 161403 Start Date*: 2015-10-15
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) DE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NO (Completed) SK (Completed) GR (Completed) AT (Completed) PL (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-005403-34 Sponsor Protocol Number: CP045/06/FCNS Start Date*: 2007-02-01
    Sponsor Name:Archimedes Development Ltd
    Full Title: An open-label study investigating long-term safety and tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the treatment of breakthrough cancer pain (BTCP) in subjects taking regular opioid...
    Medical condition: The treatment of Breakthrough Cancer Pain (BTCP) in subjects taking regular opioid therapy.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058019 Cancer pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004965-22 Sponsor Protocol Number: NN9535-4339 Start Date*: 2017-06-08
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) HU (Completed) FR (Completed) FI (Completed) ES (Completed) SE (Completed) BG (Completed) GB (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001209-22 Sponsor Protocol Number: PRINCIPLE Start Date*: 2020-03-26
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: Platform Randomised trial of INterventions against COVID-19 In older peoPLE
    Medical condition: Suspected COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10053983 Corona virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-001382-15 Sponsor Protocol Number: ATI-2042-CLN-205 Start Date*: 2007-09-20
    Sponsor Name:ARYx Therapeutics
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATI-2042 in Patients with Paroxysmal Atrial Fibrillation and Pacemakers with Atrial Fibrillation Data Logging Capabilities
    Medical condition: The trial is to investigate the efficacy of the new drug ATI-2042 to reduce the atrial tachyarrhythmia burden in patients with paroxysmal atrial fabrilation. ATI-2042 is designed to act like Amioda...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003661 Atrial fibrillation paroxysmal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002642-23 Sponsor Protocol Number: NVD-CLN01 Start Date*: 2016-11-28
    Sponsor Name:Novadip Biosciences
    Full Title: A prospective multi-centre, randomised, controlled study to evaluate the safety and preliminary effectiveness of NVD-001 for the treatment of low grade degenerative lumbar spondylolisthesis by inte...
    Medical condition: Patients diagnosed with symptomatic degenerative spondylolisthesis grade I or II with an indication for spinal fusion of one vertebral segment (L1-S1).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003291-77 Sponsor Protocol Number: GLPG1837-CL-201 Start Date*: 2016-02-02
    Sponsor Name:Galapagos NV
    Full Title: A phase IIa, open label study of multiple doses of GLPG1837 in subjects with cystic fibrosis and the G551D mutation
    Medical condition: Cystic fibrosis with the G551D mutation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003702-26 Sponsor Protocol Number: E2007-G000-208 Start Date*: 2007-01-10
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Explore the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients with Refractory Partial Seizures
    Medical condition: Refractory Partial Seizures
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061334 Partial seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LV (Completed) EE (Completed) LT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000212-34 Sponsor Protocol Number: AG348-C-018 Start Date*: 2021-10-11
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZ...
    Medical condition: Transfusion-Dependent Alpha- or Beta-Thalassemia
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004850 10081904 Transfusion dependent thalassemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003075-35 Sponsor Protocol Number: CTT116855 Start Date*: 2014-07-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase III, 52 week, randomized, double-blind, 3-arm parallel group study, comparing the efficacy, safety and tolerability of the fixed dose triple combination fluticasone furoate/ umeclidinium/vi...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) PL (Completed) SE (Completed) DE (Completed) AT (Completed) CZ (Completed) BE (Completed) DK (Completed) ES (Completed) NO (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001440-38 Sponsor Protocol Number: 42647 Start Date*: 2014-05-22
    Sponsor Name:Department of Dermatology D92, Bispebjerg Hospital
    Full Title: Methods to increase PpIX formation in the skin of healthy volunteers
    Medical condition: Healthy volunteers - no medical condition is investigated but pharmaco kinetics
    Disease: Version SOC Term Classification Code Term Level
    17.0 10022891 - Investigations 10040879 Skin investigations HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000402-38 Sponsor Protocol Number: GS-US-418-4279 Start Date*: 2018-01-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease
    Medical condition: To evaluate the testicular safety of filgotinib in adult males with moderately to severely Active Inflammatory Bowel Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    20.0 100000004856 10013099 Disease Crohns LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) PT (Prematurely Ended) NL (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) ES (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-004293-24 Sponsor Protocol Number: E2007-A001-207 Start Date*: 2006-09-26
    Sponsor Name:Eisai Limited
    Full Title: An Open-label Extension Phase of the Double-blind, Placebo-controlled, Dose-escalation, Parallel-group Study of E2007 (perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizu...
    Medical condition: E2007 is given as adjunctive, long-term treatment in patients with refractory partial onset seizures with or without secondary generalization
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) DE (Completed) CZ (Completed) GB (Completed) ES (Completed) LV (Completed) BE (Completed) FI (Completed) EE (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005326-19 Sponsor Protocol Number: NN9924-4234 Start Date*: 2016-09-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment. A 26-week randomised, double-blind, placebo-controlled trial
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 00:35:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA